Antibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity.

Sagar, Divya

Antibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity. [electronic resource] - Scientific reports 06 2017 - 2707 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

2045-2322

10.1038/s41598-017-03027-x doi


Animals
Antibodies, Blocking--pharmacology
Central Nervous System--immunology
Chemokine CCL2--metabolism
Dendritic Cells--drug effects
Encephalomyelitis, Autoimmune, Experimental--diagnosis
Endothelium, Vascular--metabolism
Immunity--drug effects
Lectins--genetics
Lectins, C-Type--antagonists & inhibitors
Mice
Mice, Knockout
Models, Biological
Myeloid Cells--drug effects
Phenotype
Protein Binding
Protein Tyrosine Phosphatase, Non-Receptor Type 11--metabolism
Protein Tyrosine Phosphatase, Non-Receptor Type 6--metabolism
Receptors, Mitogen--antagonists & inhibitors
Recurrence
Severity of Illness Index
Signal Transduction
Transendothelial and Transepithelial Migration